Skip to content

Observational Study of CT Dye Administration Through the Intraosseous Vascular Access Route

An Observational Study to Determine the Safety and Effectiveness of Intraosseous Vascular Access for the Delivery of CT Contrast Dye

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01531686
Enrollment
8
Registered
2012-02-13
Start date
2012-03-01
Completion date
2014-01-01
Last updated
2026-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients With Intraosseous Vascular Access Requiring Computed Tomography (CT) Exam

Keywords

intraosseous vascular access, Computed Tomography (CT) examination

Brief summary

An observational study to determine the safety and effectiveness of Intraosseous (IO) vascular access for delivery of contrast dye for Computed Tomography (CT) examination. The hypothesis is that IO access can be safely and effectively used to deliver contrast medium for CT examination.

Detailed description

An observational study to determine the safety and effectiveness of Proximal Humerus Intraosseous (IO) vascular access for delivery of contrast medium for Computed Tomography (CT) examination. The hypothesis is that Proximal Humerus IO access in conjunction with a pressure-limited power injection device can be safely and effectively used to deliver contrast medium for CT examination.

Interventions

PROCEDUREIntraosseous delivery of CT contrast dye

Delivery of CT contrast through intraosseous vascular access at the proximal humerus for CT examination.

Sponsors

Vidacare Corporation
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged 18 years or older * Has received intraosseous (IO) vascular access at the proximal humerus insertion site via EZ-IO 45 mm needle set, as standard of care * Requires Computed Tomography (CT) examination with contrast media delivery via proximal humerus intraosseous catheter, as standard of care * Cognitively and physically able to give written consent to participate in the study or is obtained from a Legally Authorized Representative (LAR)

Exclusion criteria

* Fracture in target bone, or significant trauma to the site * Excessive tissue and/or absence of adequate anatomical landmarks in target bone * Infection in target area * IO insertion in past 24 hours, prosthetic limb or joint or other significant orthopedic procedure in target bone * Allergy to contrast media * Imprisoned * Pregnant * Requires English language translation other than Spanish * Has received proximal humerus IO access with an IO catheter other than the EZ-IO 45 millimeter (mm) needle set system * Has existing proximal humerus IO access using the EZ-IO 45 mm needle set but IO catheter is mal-positioned or dislodged

Design outcomes

Primary

MeasureTime frameDescription
Adequacy of Computed Tomography (CT) Imageat time of CT examination average time is within 24 hoursAdequacy of CT image graded as adequate or inadequate indicating the ability to effectively administer the contrast medium needed for the indicated CT examination.
Incidence of Complication With Administration of Contrast for Computed Tomography (CT) Examinationat time of CT examination average time is within 30 minutesincidence of complications associated with the administration of contrast through the proximal humerus intraosseous (IO) route for CT examination

Countries

United States

Contacts

STUDY_DIRECTORThomas Philbeck, PhD

Sponsor Company- Vidacare Corporation

Participant flow

Recruitment details

observational study with patients enrolled in the emergency department

Baseline characteristics

Characteristic
Age, Continuous42.25 years
STANDARD_DEVIATION 11.18
Region of Enrollment
United States
8 Participants
Sex: Female, Male
Female
4 Participants
Sex: Female, Male
Male
4 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 8
other
Total, other adverse events
0 / 8
serious
Total, serious adverse events
0 / 8

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026